A review of dry eye disease therapies: exploring the qualities of varenicline solution nasal spray

References

• Moss SE, Klein R, Klein BEK. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008 Aug;85(8):668–674.
   PubMed Web of Science ®Google Scholar
• Wirta D, Vollmer P, Paauw J, et al. Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology. 2022 Apr;129(4):379–387.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017 Oct;15(4):802–812.
   Google Scholar
• Farrand KF, Fridman M, Stillman IO, et al. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–98.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017 Jul;15(3):276–283.
   PubMed Web of Science ®Google Scholar
• Venkateswaran N, Bian Y, Gupta PK. Practical guidance for the use of loteprednol etabonate ophthalmic suspension 0.25% in the management of dry eye disease. Clin Ophthalmol. 2022;16:349–355.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology. 2000 Apr;107(4):631–639.
   PubMed Web of Science ®Google Scholar
• Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharmacother. 2018 Mar;19(4):337–353.
   PubMed Web of Science ®Google Scholar
• Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, et al. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study. Ocul Surf. 2022;24:15–21.
   PubMed Web of Science ®Google Scholar
• Stern ME, Beuerman RW, Fox RI, et al. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol. 1998;438:643–651.
   PubMed Web of Science ®Google Scholar
• Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004 Mar;78(3):409–416.
   PubMed Web of Science ®Google Scholar
• Beuerman RW, Mircheff A, Pflugfelder SC, et al. The lacrimal functional unit. In: Dry eye and ocular surface disorders. Boca Raton: Taylor & Francis Group. 2004. p. 23–52.
   Google Scholar
• Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013 Feb;32(1):19–41.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Cao A, Galor A, et al. Nicotinic acetylcholine receptor stimulation: a new approach for stimulating tear secretion in dry eye disease. Ocul Surf. 2022 May;10(25):58–64.
   Google Scholar
• Lemp MA Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J. 1995 Oct;21(4):221–232.
   Google Scholar
• Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17(6):584–589.
   PubMed Web of Science ®Google Scholar
• Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren’s and non-Sjogren’s patients with dry eye. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2609–2614.
   PubMed Web of Science ®Google Scholar
• Brignole FP-J, Goldschild M, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells in patients with dry eyes. * invest ophthalmol vis sci 2000;41:1356-1363. Am J Ophthalmol. 2000 Sep;130(3):385.
   Google Scholar
• Warren DW Hormonal influences on the lacrimal gland. Int Ophthalmol Clin. Winter 1994;34(1):19–25.
   PubMedGoogle Scholar
• Schaumberg DA, Buring JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA. 2001 Nov 7;286(17):2114–2119.
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Schaumberg DA, Suzuki T, et al. Sex steroids, meibomian gland dysfunction and evaporative dry eye in Sjogren’s syndrome. Lupus. 2002;11(10):667.
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002;966:211–222.
   PubMed Web of Science ®Google Scholar
• Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000 Dec;85(12):4874–4882.
   PubMed Web of Science ®Google Scholar
• Galor A, Feuer W, Lee DJ, et al. Ocular surface parameters in older male veterans. Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1426–1433.
   PubMed Web of Science ®Google Scholar
• Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6125–6130.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Abetz L, Mertzanis P, et al. Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye. Value Health. 2005 Mar-Apr;8(2):168–174.
   PubMed Web of Science ®Google Scholar
• Galor A, Zlotcavitch L, Walter SD, et al. Dry eye symptom severity and persistence are associated with symptoms of neuropathic pain. Br J Ophthalmol. 2015 May;99(5):665–668.
   PubMed Web of Science ®Google Scholar
• Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32.
   PubMed Web of Science ®Google Scholar
• Rosenthal P, Borsook D. The corneal pain system. Part I: the missing piece of the dry eye puzzle. Ocul Surf. 2012 Jan;10(1):2–14.
   PubMed Web of Science ®Google Scholar
• Muller LJ, Marfurt CF, Kruse F, et al. Corneal nerves: structure, contents and function. Exp Eye Res. 2003 May;76(5):521–542.
   PubMed Web of Science ®Google Scholar
• Guthoff RF, Wienss H, Hahnel C, et al. Epithelial innervation of human cornea: a three-dimensional study using confocal laser scanning fluorescence microscopy. Cornea. 2005 Jul;24(5):608–613.
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4293–4301.
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2283–2292.
   PubMed Web of Science ®Google Scholar
• Bardin L. The complex role of serotonin and 5-HT receptors in chronic pain. Behav Pharmacol. 2011 Sep;22(5–6):390–404.
   PubMed Web of Science ®Google Scholar
• Moalem G, Grafe P, Tracey DJ. Chemical mediators enhance the excitability of unmyelinated sensory axons in normal and injured peripheral nerve of the rat. Neuroscience. 2005;134(4):1399–1411.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Imbe H, Tashiro A, et al. The role of peripheral 5HT2A and 5HT1A receptors on the orofacial formalin test in rats with persistent temporomandibular joint inflammation. Neuroscience. 2005;130(2):465–474.
   PubMed Web of Science ®Google Scholar
• Koltzenburg M, Torebjork HE, Wahren LK. Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. Brain. 1994 Jun;117(Pt 3):579–591.
   PubMedGoogle Scholar
• Chhadva P, Lee T, Sarantopoulos CD, et al. Human tear serotonin levels correlate with symptoms and signs of dry eye. Ophthalmology. 2015 Aug;122(8):1675–1680.
   PubMed Web of Science ®Google Scholar
• Downie LE, Hom MM, Berdy GJ, et al. An artificial tear containing flaxseed oil for treating dry eye disease: a randomized controlled trial. Ocul Surf. 2020 Jan;18(1):148–157.
   PubMed Web of Science ®Google Scholar
• Maharana PK, Raghuwanshi S, Chauhan AK, et al. Comparison of the efficacy of carboxymethylcellulose 0.5%, hydroxypropyl-guar containing polyethylene glycol 400/propylene glycol, and hydroxypropyl methyl cellulose 0.3% tear substitutes in improving ocular surface disease index in cases of dry eye. Middle East Afr J Ophthalmol. 2017 Oct-Dec;24(4):202–206.
   PubMedGoogle Scholar
• Garrigue JS, Amrane M, Faure MO, et al. Relevance of lipid-based products in the management of dry eye disease. J Ocul Pharmacol Ther. 2017 Nov;33(9):647–661.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017 Nov;124(11S):S4–S13.
   PubMed Web of Science ®Google Scholar
• Cubuk MO, Ucgul AY, Ozgur A, et al. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren’s syndrome versus non-Sjogren’s syndrome. Int Ophthalmol. 2021 Apr;41(4):1479–1485.
   PubMed Web of Science ®Google Scholar
• Mandal A, Gote V, Pal D, et al. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa(R)) for dry eye disease. Pharm Res. 2019 Jan 7;36(2):36.
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Perry HD, Nattis AS, et al. Lifitegrast for the treatment of dry eye disease in adults. Expert Opin Pharmacother. 2017 Oct;18(14):1517–1524.
   PubMed Web of Science ®Google Scholar
• Haber SL, Benson V, Buckway CJ, et al. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366.
   Web of Science ®Google Scholar
• Bui TM, Wiesolek HL, Sumagin RICAM-1. A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020 Sep;108(3):787–799.
   PubMed Web of Science ®Google Scholar
• Beckman K, Katz J, Majmudar P, et al. Loteprednol etabonate for the treatment of dry eye disease. J Ocul Pharmacol Ther. 2020 Sep;36(7):497–511.
   PubMed Web of Science ®Google Scholar
• Clark D, Tauber J, Sheppard J, et al. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease. Am J Ophthalmol. 2021;226:22–31.
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. Corrigendum to “TFOS DEWS II pathophysiology report” [Ocul. Surf. 15 (3) (2017) 438-510]. Ocul Surf. 2019 Oct;17(4):842.
   PubMed Web of Science ®Google Scholar
• Sabeti S, Kheirkhah A, Yin J, et al. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020 Mar - Apr;65(2):205–217.
   PubMed Web of Science ®Google Scholar
• Tauber J, Wirta DL, Sall K, et al. A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea. 2021 Sep 1;40(9):1132–1140.
   PubMed Web of Science ®Google Scholar
• Wei Y, Troger A, Spahiu V, et al. The role of SKQ1 (Visomitin) in inflammation and wound healing of the ocular surface. Ophthalmol Ther. 2019 Mar;8(1):63–73.
   PubMed Web of Science ®Google Scholar
• Petrov A, Perekhvatova N, Skulachev M, et al. SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model. Adv Ther. 2016 Jan;33(1):96–115.
   PubMed Web of Science ®Google Scholar
• Lora A, Wang J, Parel JM, et al. Lacrimal nerve stimulation by a neurostimulator for tear production. Invest Ophthalmol Vis Sci. 2009;50(13):4244.
   PubMedGoogle Scholar
• Yu MD, Park JK, Kossler AL. Stimulating tear production: spotlight on neurostimulation. Clin Ophthalmol. 2021;15:4219–4226.
   PubMed Web of Science ®Google Scholar
• Dartt DA. Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases. Prog Retin Eye Res. 2009 May;28(3):155–177.
   PubMed Web of Science ®Google Scholar
• Brinton M, Kossler AL, Patel ZM, et al. Enhanced tearing by electrical stimulation of the anterior ethmoid nerve. Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):2341–2348.
   PubMed Web of Science ®Google Scholar
• Gumus K, Pflugfelder SC Intranasal tear neurostimulation: an emerging concept in the treatment of dry eye. Int Ophthalmol Clin. Spring 2017;57(2):101–108.
   PubMedGoogle Scholar
• LeDoux MS, Zhou Q, Murphy RB, et al. Parasympathetic innervation of the meibomian glands in rats. Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2434–2441.
   PubMed Web of Science ®Google Scholar
• Labetoulle M, Baudouin C, Calonge M, et al. Role of corneal nerves in ocular surface homeostasis and disease. Acta Ophthalmol. 2019 Mar;97(2):137–145.
   PubMed Web of Science ®Google Scholar
• Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease-past, present, and future. Ocul Surf. 2019 Jan;17(1):20–27.
   PubMed Web of Science ®Google Scholar
• Zilstorff-Pedersen K. Quantitative measurements of the nasolacrimal reflex. Acta Otolaryngol. 1959 Nov-Dec;50:501–506.
   PubMedGoogle Scholar
• Cometto-Muñiz CS JE. Trigeminal chemesthesis. Doty RL, editor. Handbook of olfaction and gustation: John Wiley & Sons; 2015.
   Google Scholar
• Simons EC CT. Olfaction & Taste. The Sense: A Comprehensive Reference; Amsterdam. 2008.
   Google Scholar
• Irritation. In: Green BG, Mason JR, Kare MR, editors. Chemical Senses, Vol. 2. 1990. New York: Marcel Dekker.
   Google Scholar
• TRUETEAR Product Information Allegran TechAlliance cited 2022 May 12. Available from: https://www.allergantechalliance.com/Product-Information-TrueTear
   Google Scholar
• Gupta A, Heigle T, Pflugfelder SC. Nasolacrimal stimulation of aqueous tear production. Cornea. 1997 Nov;16(6):645–648.
   PubMed Web of Science ®Google Scholar
• Alimohammadi H, Silver WL. Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat. Chem Senses. 2000 Feb;25(1):61–66.
   PubMed Web of Science ®Google Scholar
• Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 study group. Arch Intern Med. 1999 Jan 25;159(2):174–181.
   PubMedGoogle Scholar
• Shih KC, Lun CN, Jhanji V, et al. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm (Lond). 2017;14:26.
   PubMed Web of Science ®Google Scholar
• Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004 Jul;138(1):6–17.
   PubMed Web of Science ®Google Scholar
• Bordia T, Hrachova M, Chin M, et al. Varenicline is a potent partial agonist at alpha6beta2* nicotinic acetylcholine receptors in rat and monkey striatum. J Pharmacol Exp Ther. 2012 Aug;342(2):327–334.
   PubMed Web of Science ®Google Scholar
• Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006 Sep;70(3):801–805.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Arons C, Rollema H, et al. Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations. Curr Med Res Opin. 2020 May;36(5):713–730.
   PubMed Web of Science ®Google Scholar
• Livingstone-Banks J, Lindson N, Hartmann-Boyce J, et al. Effects of interventions to combat tobacco addiction: cochrane update of 2019 and 2020 reviews. Addiction. 2022 Jun;117(6):1573–1588.
   PubMed Web of Science ®Google Scholar
• Drug approval package: chantix (varenicline): U.S. food & drug administration; 2006 [cited 2022 May 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021928_s000_chantixtoc.cfm#:~:text=Approval%20Date%3A%2005%2F10%2F2006
   Google Scholar
• Wirta D, Torkildsen GL, Boehmer B, et al. ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease. Cornea. 2022;41(10):1207–1216 .
   Web of Science ®Google Scholar
• Tyrvaya (varenicline solution): oyster Point Pharma; cited 2022 May 12. Available from: https://www.tyrvaya-pro.com/
   Google Scholar
• Nau J, Wyatt DJ, Rollema H, et al. A phase I, open-label, randomized, 2-way crossover study to evaluate the relative bioavailability of intranasal and oral varenicline. Clin Ther. 2021 Sep;43(9):1595–1607.
   PubMed Web of Science ®Google Scholar